Janus Kinase Inhibitors Weaken Cell Defenses Against Viral Infections
Janus kinase (JAK) inhibitors, commonly prescribed for inflammatory conditions like rheumatoid arthritis, may impair the body’s immune defense against serious viral pathogens including influenza and SARS-CoV-2. Researchers at the Norwegian University of Science and Technology published these findings in NAR Molecular Medicine, demonstrating that the medications suppress critical immune signaling pathways and reduce the activity of infection-fighting genes.
Laboratory Findings on Immune Pathway Suppression
The study investigated how JAK inhibitors affect cellular defense mechanisms against viral threats. The research team examined the impact of drugs such as baricitinib across cellular models representing lung, eye, and brain tissues. Erlend Ravlo, a doctoral researcher and lead author of the study, noted that while these medications effectively reduce inflammation for autoimmune conditions, they do so by blocking an essential immune signaling pathway that protects healthy cells from viral attacks. Alexander Yanevski, a co-author of the study, explained that the intervention lowers the activity of specific genes responsible for combating viral infections, thereby weakening the primary layer of antiviral protection. This pathway plays a central role in coordinating the body’s response when viruses attempt to infect healthy tissues. Laboratory experiments demonstrated that these medications can disrupt interferon-associated immune pathways, which are proteins that help cells activate their defenses against viruses, thereby limiting their ability to resist infection and restrict its spread.
Implications for Virus Transmission and Patient Care
The research highlights potential risks for patients prescribed JAK inhibitors during active viral outbreaks or when harboring latent infections. The findings suggest that clinicians should exercise caution when prescribing these anti-inflammatory drugs during periods of high viral circulation, as reported by the Norwegian University of Science and Technology. Conversely, the immunosuppressive properties of these medications may assist researchers in controlled laboratory settings for evaluating antiviral drugs or developing vaccines. However, the experiments do not prove on their own that using these medications increases the risk of viral infection in patients, and the study emphasizes the importance of following a doctor’s guidance without stopping treatment or changing doses without consultation.
Frequently Asked Questions About JAK Inhibitors and Viral Defense
Which specific viruses were tested in the Norwegian University of Science and Technology study?
Researchers tested the impact of JAK inhibitors on several pathogens, including Rift Valley fever virus, influenza A, adenoviruses, and SARS-CoV-2, which causes COVID-19.
Which specific JAK inhibitor medication was evaluated in the laboratory experiments?
The research team specifically tested baricitinib alongside other broad-use Janus kinase inhibitors using laboratory-grown organ models and cellular tissue samples.
What primary biological mechanism did the drugs disrupt?
The medications suppressed interferon-associated immune signaling pathways and reduced the activity of genes responsible for protecting healthy cells and fighting off viral replication.
Related reading